Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Economic evaluation of treatments for patients with localized prostate cancer in Europe, a systematic review

  • Becerra, Virginia|||0000-0002-8811-3899
  • Ávila, Mónica|||0000-0001-9583-5104
  • Jimenez, Jorge
  • Cortes Sanabria, Laura|||0000-0002-2828-3896
  • Pardo Cladellas, Yolanda|||0000-0003-4982-5495
  • Garin, Olatz|||0000-0001-6193-0779
  • Pont, Angels|||0000-0002-0602-552X
  • Alonso, Jordi|||0000-0001-8627-9636
  • Cots Reguant, Francesc|||0000-0003-0238-8902
  • Ferrer Forés, Maria Montserrat|||0000-0001-9867-7391
Background: Our objective was to assess the efficiency of treatments in patients with localized prostate cancer, by synthesizing available evidence from European economic evaluations through systematic review. Methods: Articles published 2000-2015 were searched in MEDLINE, EMBASE and NHS EED (Prospero protocol CRD42015022063). Two authors independently selected studies for inclusion and extracted the data. A third reviewer resolved discrepancies. We included European economic evaluations or cost comparison studies, of any modality of surgery or radiotherapy treatments, regardless the comparator/s. Drummond's Checklist was used for quality assessment. Results: After reviewing 8,789 titles, 13 European eligible studies were included: eight cost-utility, two cost-effectiveness, one cost-minimization, and two cost-comparison analyses. Of them, five compared interventions with expectant management, four contrasted robotic with non robotic-assisted surgery, three assessed new modalities of radiotherapy, and three compared radical prostatectomy with brachytherapy. All but two studies scored ≥8 in the quality checklist. Considering scenario and comparator, three interventions were qualified as dominant strategies (active surveillance, robotic-assisted surgery and IMRT), and six were cost-effective (radical prostatectomy, robotic-assisted surgery, IMRT, proton therapy, brachytherapy, and 3DCRT). However, QALY gains in most of them were small. For interventions considered as dominant strategies, QALY gain was 0.013 for active surveillance over radical prostatectomy; and 0.007 for robotic-assisted over non-robotic techniques. The highest QALY gains were 0.57-0.86 for radical prostatectomy vs watchful waiting, and 0.72 for brachytherapy vs conventional radiotherapy. Conclusions: Currently, relevant treatment alternatives for localized prostate cancer are scarcely evaluated in Europe. Very limited available evidence supports the cost-effectiveness of radical prostatectomy over watchful waiting, brachytherapy over radical prostatectomy, and new treatment modalities over traditional procedures. Relevant disparities were detected among studies, mainly based on effectiveness. These apparently contradictory results may be reflecting the difficulty of interpreting small differences between treatments regarding QALY gains.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Health-related quality of life in men with prostate cancer undergoing active surveillance versus radical prostatectomy, external-beam radiotherapy, prostate brachytherapy and reference population, a cross-sectional study

  • Sureda, A.
  • Fumadó, Lluís|||0000-0003-3996-167X
  • Ferrer Forés, Maria Montserrat|||0000-0001-9867-7391
  • Garin, Olatz|||0000-0001-6193-0779
  • Bonet, Xavier
  • Castells-Esteve, Manel|||0000-0003-2370-2008
  • Mir, M. C.
  • Abascal, Jose Maria|||0000-0001-8374-6593
  • Vigués, Francesc|||0000-0003-3717-6301
  • Cecchini, Lluís|||0000-0002-8873-0969
  • Suárez, J. F.
The purpose of this study is to describe Health-Related Quality of Life (HRQoL) of localized prostate cancer patients in an Active Surveillance (AS) program, and to compare them with those undergoing radical prostatectomy (RP), external-beam radiotherapy (XRT) and brachytherapy (BT). Multi-institutional pooled cross-sectional analysis on patients in an AS protocol: 75 years old; pathologically confirmed LPC (maximum of three positive cylinders); Gleason score 3 + 4; clinical stage T1a-T2b; and PSA < 15 ng/ml. Exclusion criteria for this study were: less than 6 months in AS, termination of AS protocol, or incomplete data. Patients in AS were matched with those treated with RP, XRT or BT from the 'Spanish Multicentric Study of Clinically Localized Prostate Cancer' cohort according to risk group, time from treatment selection to HRQoL survey, and age. Prostate-specific (EPIC) and generic (SF-36) HRQoL instruments were completed. Analysis was stratified by HRQoL survey moment (.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

EuroQol (EQ-5D-5L) Validity in Assessing the Quality of Life in Adults With Asthma, Cross-Sectional Study

  • Hernandez, Gimena|||0000-0001-5319-3465
  • Garin, Olatz|||0000-0001-6193-0779
  • Dima, Alexandra Lelia|||0000-0002-3106-2242
  • Pont, Angels|||0000-0002-0602-552X
  • Martí Pastor, Marc|||0000-0001-6189-2178
  • Alonso, Jordi|||0000-0001-8627-9636
  • Van Ganse, Eric|||0000-0002-7463-9187
  • Laforest, Laurent|||0000-0002-3694-7699
  • de Bruin, Marijn|||0000-0003-3100-6803
  • Mayoral, K.|||0000-0002-7904-4422
  • Serra Sutton, Vicky|||0000-0002-7852-175X
  • Ferrer Forés, Maria Montserrat|||0000-0001-9867-7391
The EuroQol-5 Dimension (EQ-5D), developed in 1990, is a most widely used generic tool to measure the health-related quality of life (HRQoL) and considered suitable for patients with asthma. In 2009, the EuroQol Group developed a new EQ-5D version to overcome limitations related to its consistently reported high ceiling effect. To enhance the sensitivity for assessing the HRQoL in further patient populations, the number of responses of EQ-5D was increased from 3 to 5 levels (EQ-5D-5L). Moreover, the availability of well-defined requirements for its Web-based administration allows EQ-5D-5L use to monitor the HRQoL in electronic health (eHealth) programs. No study has evaluated the metric properties of the new EQ-5D-5L in patients with asthma yet. This study aims to examine the distribution, construct validity, and reliability of the new EQ-5D-5L questionnaire administered online to adults with asthma. We evaluated patients with asthma (age: 18-40 years) from a primary care setting in France and England, who self-completed the EQ-5D-5L questionnaire online. The inclusion criteria were persistent asthma defined as.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Head-to-head comparison between the EQ-5D-5L and the EQ-5D-3L in general population health surveys

  • Martí Pastor, Marc|||0000-0001-6189-2178
  • Pont, Angels|||0000-0002-0602-552X
  • Ávila, Mónica|||0000-0001-9583-5104
  • Garin, Olatz|||0000-0001-6193-0779
  • Vilagut, Gemma|||0000-0002-3714-226X
  • Forero, Carlos G.|||0000-0002-5245-0076
  • Pardo Cladellas, Yolanda|||0000-0003-4982-5495
  • Tresserras, Ricard
  • Medina-Bustos, Antonia
  • Garcia-Codina, Oriol
  • Cabasés, Juan
  • Rajmil, Luis|||0000-0002-6625-0649
  • Alonso, Jordi|||0000-0001-8627-9636
  • Ferrer Forés, Maria Montserrat|||0000-0001-9867-7391
The EQ-5D has been frequently used in national health surveys. This study is a head-to-head comparison to assess how expanding the number of levels from three (EQ-5D-3L) to five in the new EQ-5D-5L version has improved its distribution, discriminatory power, and validity in the general population. A representative sample (N = 7554) from the Catalan Health Interview Survey 2011-2012, aged ≥18, answered both EQ-5D versions, and we evaluated the response redistribution and inconsistencies between them. To assess validity of this redistribution, we calculated the mean of the Visual Analogue Scale (VAS), which measures perceived health. The discriminatory power was examined with Shannon Indices, calculated for each dimension separately. Spanish preference value sets were applied to obtain utility indices, examining their distribution with statistics of central tendency and dispersion. We estimated the proportion of individuals reporting the best health state in EQ-5D-5L and EQ-5D-3L within groups of specific chronic conditions and their VAS mean. A very small reduction in the percentage of individuals with the best health state was observed, from 61.8% in EQ-5D-3L to 60.8% in EQ-5D-5L. In contrast, a large proportion of individuals reporting extreme problems in the 3 L version moved to severe problems (level 4) in the 5 L version, particularly for pain/discomfort (75.5%) and anxiety/depression (66.4%). The average proportion of inconsistencies was 0.9%. The pattern of the perceived health VAS mean confirmed the hypothesis established a priori, supporting the validity of the observed redistribution. Shannon index showed that absolute informativity was higher in the 5 L version for all dimensions. The means (SD) of the Spanish EQ-5D-3L and EQ-5D-5L indices were 0.87 (0.25) and 0.89 (0.22). The proportion of individuals with the best health state within each specific chronic condition was very similar, regardless of the EQ-5D version (≤ 30% in half of the 28 chronic conditions). Although the proportion of individuals with the best possible health state is still very high, our findings support that the increase of levels provided by the EQ-5D-5L contributed to the validity and discriminatory power of this new version to measure health in general population, as in the national health surveys. The online version of this article (10.1186/s12963-018-0170-8) contains supplementary material, which is available to authorized users.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Health-related quality of life inequalities by sexual orientation, Results from the Barcelona Health Interview Survey

  • Martí Pastor, Marc|||0000-0001-6189-2178
  • Pérez Albarracín, Glòria|||0000-0001-6653-3393
  • German, Danielle
  • Pont, Angels|||0000-0002-0602-552X
  • Garin, Olatz|||0000-0001-6193-0779
  • Alonso, Jordi|||0000-0001-8627-9636
  • Gotsens, Mercè|||0000-0003-2952-2024
  • Ferrer Forés, Maria Montserrat|||0000-0001-9867-7391
Studies on health-related quality of life (HRQoL) inequalities according to sexual orientation are scarce. The aim of this study was to assess HRQoL inequalities between lesbian, gay, and bisexual (LGB) people and heterosexuals in the 2011 Barcelona population, to describe the extent to which sociodemographic characteristics, health-related behaviors, and chronic conditions could explain such inequalities, and to understand if they are sexual orientation inequities. In the 2011 Barcelona Health Interview Survey 3277 adults answered the EQ-5D, which measures five dimensions of HRQoL summarized into a single utility index (1 = perfect health, 0 = death). To assess HRQoL differences by sexual orientation we constructed Tobit models for the EQ-5D index, and Poisson regression models for the EQ-5D dimensions. In both cases, nested models were constructed to assess the mediator role of selected variables. After adjusting by socio-demographic variables, the LGB group presented a significantly lower EQ-5D index than heterosexuals, and higher prevalence ratios of problems in physical EQ-5D dimensions among both genders: adjusted prevalence ratio (aPR) = 1.70 for mobility (p = 0.046) and 2.11 for usual activities (p = 0.019). Differences in mental dimensions were only observed among men: aPR = 3.15 for pain/discomfort (p = 0.003) and 2.49 for anxiety/depression (p = 0.030). All these differences by sexual orientation disappeared after adding chronic conditions and health-related behaviors in the models. The LGB population presented worse HRQoL than heterosexuals in the EQ-5D index and most dimensions. Chronic conditions, health-related behaviors and gender play a major role in explaining HRQoL differences by sexual orientation. These findings support the need of including sexual orientation into the global agenda of health inequities.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Impact of asthma on women and men, Comparison with the general population using the EQ-5D-5L questionnaire

  • Hernandez, Gimena|||0000-0001-5319-3465
  • Dima, Alexandra Lelia|||0000-0002-3106-2242
  • Pont, Angels|||0000-0002-0602-552X
  • Martí Pastor, Marc|||0000-0001-6189-2178
  • Alonso, Jordi|||0000-0001-8627-9636
  • Van Ganse, Eric|||0000-0002-7463-9187
  • Laforest, Laurent|||0000-0002-3694-7699
  • de Bruin, Marijn|||0000-0003-3100-6803
  • Mayoral, K.|||0000-0002-7904-4422
  • Ferrer Forés, Maria Montserrat|||0000-0001-9867-7391
The aim was to evaluate the impact of asthma on patients' Health-Related Quality of Life (HRQoL) by comparing asthmatic women and men with reference norms, to examine the factors which contributed to an impaired HRQoL, and to identify groups at higher risk. Cross-sectional evaluation of 222 primary care patients with persistent asthma (18-40 years old). HRQoL impact was estimated with the EuroQol-5 Dimensions (EQ-5D), which allows calculating Quality-Adjusted Life-Years (QALYs) by applying society preferences. Participants self-completed the EQ-5D questionnaire online. Telephonic interviews collected information on medication and adherence, and administered the Asthma Control Questionnaire. Severity markers included asthma-related comorbidity, previous oral corticosteroids course prescription, and inhaled corticosteroids daily dose. After bivariate analyses, multiple linear regression models were constructed to examine the relations between HRQoL asthma impact and socio-demographic and clinical variables, using as dependent variable the deviation from general population-based EQ-5D reference norms. Deviation from the EQ-5D index norms was moderate in most age/gender groups (-0.1, which corresponds to 0.6 standard deviations), while it was large in women aged 18-24 years (-0.18, corresponding to 1.1 standard deviations). In regression models, a poor asthma control was the only factor independently associated to HRQoL impact in both women and men: β -0.18 (p<0.001) and -0.15 (p = 0.01) respectively. Translating these β coefficients to QALYs, they are interpretable as 66 fewer days of full health per year in women with uncontrolled asthma and 55 for men, compared with those with controlled asthma. Persistent asthma has a moderately negative HRQoL impact on patients of both genders, and the youngest women have been identified as a high risk group which merits further research. We identified asthma control as the major contributor to impaired HRQoL in patients, regardless of their gender, suggesting that asthma HRQoL impact could be alleviated by achieving a good control of symptoms.